Tag:
vismodegib
Latest Headlines
Latest Headlines
Roche rushes new cancer drug to regulators on Ph2 data
When Roche tried to gain an approval to use T-DM1 against breast cancer based on mid-stage results from a single-arm study, the FDA sent its regulatory team packing--refusing to even review the
Roche preps vismodegib app with "profound" efficacy data
Armed with positive data from a pivotal Phase II trial, Lexington, MA-based Curis is waiting for its partner Roche to begin its long-awaited pitch to gain FDA approval for a new treatment for
Roche preps vismodegib app after Ph2 skin cancer success
Roche and Genentech have posted a fresh set of promising mid-stage data on vismodegib , a cancer drug it's collaborating on with Lexington, MA-based Curis. In what investigators describe as a pivotal
Roche tees up new app on promising Ph2 cancer drug
Lexington, MA-based Curis ( $CRIS ) is eagerly spreading the news that its partners at Roche/Genentech have wrapped a positive mid-stage trial for an experimental new treatment for advanced basal cell
